Monthly Prescribing Reference

Par Launches Generic Megace ES

Par Pharmaceuticals announced the launch of Megestrol Acetate Suspension, the generic version of its brand Megace ES. Megace ES is a progestin indicated for the treatment of anorexia, cachexia, or ...
Courthouse News Service

Drugmaker Par Will Pay $45 Million

NEWARK (CN) - Par Pharmaceuticals pleaded guilty and will pay $45 million in criminal and civil fines for promoting its anorexia drug Megace ES for off-label uses, federal prosecutors said. Doctors ...
Reuters

U.S. drugmaker admits misbranding AIDS appetite medicine

March 5 (Reuters) - Par Pharmaceutical Cos, a generic drugmaker, has pleaded guilty to improperly marketing a medication intended to address appetite loss in AIDS patients, and agreed to pay $45 ...
FiercePharma

Par Pharmaceuticals Pleads Guilty and Agrees to Pay $45 Million to Resolve Civil and Criminal Allegations Related to Off-Label Marketing

Tuesday, March 5, 2013--New Jersey-based Par Pharmaceutical Companies Inc. pleaded guilty in federal court today and agreed to pay $45 million to resolve its criminal and civil liability in the ...
FiercePharma

Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Me

WOODCLIFF LAKE, N.J., Oct. 14, 2011 /PRNewswire via COMTEX/ -- Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par Pharmaceutical Companies, Inc. /quotes ...
Reuters

Judge will not block sale of generic drug for AIDS and cancer patients

(Reuters) - A Maryland judge on Thursday refused to block TWi Pharmaceuticals from marketing a generic version of Megace ES while brand-name manufacturer Par Pharmaceutical challenges a recent ruling ...
Medscape

FDA Approvals: BiDil, Megace ES, Aczone

July 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved isosorbide dinitrate/hydralazine HCl tablets for use in self-identified black patients as an adjunct to standard heart failure ...
MarketWatch

Par Pharmaceutical wins FDA approval for Megace ES

LONDON (MarketWatch) -- Par Pharmaceutical Companies said it's won Food and Drug Administration approval for Megace ES, a treatment for anorexia, cachexia or AIDS-related weight loss. Par said Megace ...
Seeking Alpha

Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call Transcript

Good day, ladies and gentlemen, and welcome to Par Pharmaceutical's First Quarter 2008 Earnings Call. My name is Jasmine, and I will the operator for today. (Operator Instructions). I would now like ...
Monthly Prescribing Reference

TWi Launches Generic Megace ES

TWi Pharmaceuticals announced the launch of Megestrol Acetate Suspension, the generic version of Par Pharmaceutical’s Megace ES. Megace ES is a progestin indicated for the treatment of anorexia, ...
Seeking Alpha

Par Pharmaceutical Companies, Inc. Q2 2008 Earnings Call Transcript

Good day, ladies and gentlemen, and welcome to the Second Quarter 2008 Par Pharmaceutical Conference Call. My name is Karen, and I will be your coordinated for today. At this time, all participants ...